SAGE Therapeutics is a central nervous system (CNS) product focused company building a portfolio of new therapies to meet the growing unmet medical needs resulting from a range of CNS disorders, including schizophrenia, depression, pain and traumatic brain injury. SAGE Therapeutics’ proprietary Positive and Negative Allosteric Modulator (PANAM) chemistry platform targets the primary excitatory and inhibitory neurotransmitter systems in the brain and enables the development of allosteric modulators that fine tune and balance neuronal activity that is disrupted in CNS disorders. Specifically, SAGE Therapeutics is focused on non-benzodiazepine and non-glycine approaches to modulating GABA and glutamate receptors, respectively.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 10/01/11 | Series A | 35M | Unknown |
People
Steven Paul (Founder, CSO)
Kiran Reddy (Head of Business Development and Operations)
Kevin Starr (CEO)
News
Dogpatch Labs welcomes new Cambridge startups
May 15, 2010 1:26 am
Dogpatch Labs, the “frathouse for geeks” run by Polaris Ventures, is welcoming a new batch of companies to its Cambridge,… Continue reading ⟩
Life sciences briefing: Monday, Oct. 22, 2007
October 22, 2007 3:23 pm
Featured companies: Ablynx, Avant Immunotherapeutics, BioForm Medical, Celldex Therapeutics, Genomas, High-Throughput Genomics, Orchid Cellmark, ReliaGene Technologies, SarCode, TransMolecular, VisEn Medical… Continue reading ⟩
Life sciences briefing: Thursday, Sept. 27, 2007
September 27, 2007 2:32 pm
Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium International, New Ortho Polymers, Osprey Pharmaceuticals, Othera Pharmaceuticals, StrataGent Life Sciences… Continue reading ⟩